Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 1;80(5):429-430.
doi: 10.1001/jamaneurol.2023.0123.

A Step Forward in the Fight Against Dementia-Are We There Yet?

David A Wolk  1 , Gil D Rabinovici  2   3 , Bradford C Dickerson  4
Affiliations

A Step Forward in the Fight Against Dementia-Are We There Yet?

David A Wolk et al. JAMA Neurol. .
No abstract available

Plain language summary

This Viewpoint reports on the results of the Clarity AD trial, a phase 3 randomized clinical trial of lecanemab for patients with early Alzheimer disease, in which lecanemab’s clinical efficacy was demonstrated using well-established outcome measures.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest:

D.A.W. has served as a paid consultant to Eli Lilly, GE Healthcare, and Qynapse. He serves on a DSMB for Functional Neuromodulation. He receives research support paid to his institution from Biogen who have developed lecanemab.

G.D.R. receives research support paid to his institution from Avid Radiopharmaceuticals, GE Healthcare, Life Molecular Imaging and Genentech. In the past three years, he has served as a paid consultant to Alector, Eli Lilly, Genentech, Merck and Roche. He served on a DSMB for Johnson & Johnson. He is an Associate Editor for JAMA Neurology.

B.C.D. has served in the past three years as a paid consultant to Acadia, Alector, Arkuda, Denali, Eisai who have developed lecanemab, Genentech, Lilly, Merck, Takeda, and Wave Lifesciences. He serves on a DSMB for Lilly and Merck.

References

    1. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. Lecanemab in Early Alzheimer’s Disease. N Engl J Med 2022, 10.1056/NEJMoa2212948. Epub 2022/12/01. - DOI - PubMed
    1. Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks J, Sims JR, Brys M, Apostolova LG, Salloway SP, Skovronsky DM. Donanemab in Early Alzheimer’s Disease. N Engl J Med 2021;384(18):1691–704. Epub 2021/03/16. - PubMed
    1. Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, von Hehn C, Iwatsubo T, Mallinckrodt C, Mummery CJ, Muralidharan KK, Nestorov I, Nisenbaum L, Rajagovindan R, Skordos L, Tian Y, van Dyck CH, Vellas B, Wu S, Zhu Y, Sandrock A. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease. J Prev Alzheimers Dis 2022;9(2):197–210. Epub 2022/05/12. - PubMed
    1. Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol 2017;134(2):171–86. Epub 2017/05/11. - PMC - PubMed
    1. Boyle PA, Yu L, Leurgans SE, Wilson RS, Brookmeyer R, Schneider JA, Bennett DA. Attributable risk of Alzheimer’s dementia attributed to age-related neuropathologies. Ann Neurol 2019;85(1):114–24. Epub 2018/11/14. - PMC - PubMed